JP2011522842A - パーキンソン病に関連する症状の治療のための化合物 - Google Patents

パーキンソン病に関連する症状の治療のための化合物 Download PDF

Info

Publication number
JP2011522842A
JP2011522842A JP2011512782A JP2011512782A JP2011522842A JP 2011522842 A JP2011522842 A JP 2011522842A JP 2011512782 A JP2011512782 A JP 2011512782A JP 2011512782 A JP2011512782 A JP 2011512782A JP 2011522842 A JP2011522842 A JP 2011522842A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
compound according
tyrosine
mimotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522842A5 (https=
Inventor
マルクス・マントラー
フランク・マットナー
ヴァルター・シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0095108A external-priority patent/AT506819B1/de
Priority claimed from AT0095208A external-priority patent/AT506820B1/de
Application filed by Affiris AG filed Critical Affiris AG
Publication of JP2011522842A publication Critical patent/JP2011522842A/ja
Publication of JP2011522842A5 publication Critical patent/JP2011522842A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011512782A 2008-06-12 2009-06-12 パーキンソン病に関連する症状の治療のための化合物 Pending JP2011522842A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AT0095108A AT506819B1 (de) 2008-06-12 2008-06-12 Vakzin zur behandlung von alzheimer-krankheit
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA951/2008 2008-06-12
ATA952/2008 2008-06-12
PCT/AT2009/000237 WO2009149487A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease

Publications (2)

Publication Number Publication Date
JP2011522842A true JP2011522842A (ja) 2011-08-04
JP2011522842A5 JP2011522842A5 (https=) 2012-07-19

Family

ID=41417160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512782A Pending JP2011522842A (ja) 2008-06-12 2009-06-12 パーキンソン病に関連する症状の治療のための化合物

Country Status (12)

Country Link
US (2) US20110092436A1 (https=)
EP (1) EP2310032A2 (https=)
JP (1) JP2011522842A (https=)
KR (1) KR20110036809A (https=)
CN (1) CN102123726A (https=)
AU (1) AU2009257170B2 (https=)
BR (1) BRPI0915134A2 (https=)
CA (1) CA2723995A1 (https=)
IL (1) IL209896A0 (https=)
MX (1) MX2010013647A (https=)
RU (1) RU2011100127A (https=)
WO (1) WO2009149487A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
WO2016131420A1 (zh) * 2015-02-17 2016-08-25 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN106632607A (zh) * 2016-12-29 2017-05-10 华东理工大学 靶向survivin纳米抗体及其制备方法和应用
TWI705975B (zh) 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
CN110156887B (zh) * 2018-02-12 2023-01-13 中国人民解放军军事科学院军事医学研究院 人vasn蛋白抗原表位、抗原模拟表位及其用途
CN108676071B (zh) * 2018-05-24 2021-05-14 华南理工大学 一种抗Aβ蛋白聚集的七肽及其应用与编码该合成多肽的基因
CN108676072B (zh) * 2018-05-24 2021-05-14 华南理工大学 一种具有抗Aβ42蛋白聚集功能的多肽及其应用与编码该多肽的基因
CN111040020B (zh) * 2018-12-28 2022-04-12 中国人民解放军军事科学院军事医学研究院 一种烯烃硫醚类订书肽及其制备方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041067A2 (en) * 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2004062556A2 (en) * 2003-01-14 2004-07-29 Frank Mattner Methods for preventing and treating alzheimer’s disease (ad)
JP2005330231A (ja) * 2004-05-20 2005-12-02 Otsuka Pharmaceut Co Ltd 医薬組成物
WO2006005707A2 (en) * 2004-07-13 2006-01-19 Affiris Forschungs- Und Entwicklungs Gmbh Method for preventing and treating alzheimer´s disease
WO2006083689A2 (en) * 2005-01-28 2006-08-10 Elan Pharma International Limited Anti a beta antibody formulation
US20060280743A1 (en) * 2000-12-06 2006-12-14 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2011511841A (ja) * 2008-02-12 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022748A3 (cs) * 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US20050176030A1 (en) * 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280743A1 (en) * 2000-12-06 2006-12-14 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2004041067A2 (en) * 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2004062556A2 (en) * 2003-01-14 2004-07-29 Frank Mattner Methods for preventing and treating alzheimer’s disease (ad)
JP2005330231A (ja) * 2004-05-20 2005-12-02 Otsuka Pharmaceut Co Ltd 医薬組成物
WO2006005707A2 (en) * 2004-07-13 2006-01-19 Affiris Forschungs- Und Entwicklungs Gmbh Method for preventing and treating alzheimer´s disease
WO2006083689A2 (en) * 2005-01-28 2006-08-10 Elan Pharma International Limited Anti a beta antibody formulation
JP2011511841A (ja) * 2008-02-12 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体

Also Published As

Publication number Publication date
CA2723995A1 (en) 2009-12-17
EP2310032A2 (en) 2011-04-20
KR20110036809A (ko) 2011-04-11
BRPI0915134A2 (pt) 2016-02-16
CN102123726A (zh) 2011-07-13
US20110092436A1 (en) 2011-04-21
MX2010013647A (es) 2011-04-05
WO2009149487A3 (en) 2010-07-29
RU2011100127A (ru) 2012-07-20
IL209896A0 (en) 2011-02-28
AU2009257170B2 (en) 2014-06-12
US20130287807A1 (en) 2013-10-31
WO2009149487A2 (en) 2009-12-17
AU2009257170A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
JP6041917B2 (ja) 疾患を治療するための化合物
JP2011522842A (ja) パーキンソン病に関連する症状の治療のための化合物
JP5989074B2 (ja) アミロイドーシス治療のための化合物
JP6410764B2 (ja) 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン
HK1152470B (en) Peptides for treating beta-amyloidoses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805